SGMT — Sagimet Biosciences Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1400118 ·
Last close
$9.85
Market Cap
$702.97M
52W High
$11.45
52W Low
$4.50
ADV30
1,174,100
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -21,567,000 | -19,149,000 | 282,093,000 | 110,960,000 | 39,912,000 |
| Jun 2026 | 0 | — | -15,818,000 | -13,953,000 | 263,430,000 | 165,896,000 | 7,275,000 |
| Mar 2026 | 0 | — | -11,713,000 | -10,650,000 | 107,755,000 | 36,626,000 | 5,297,000 |
| Dec 2025 | 0 | — | -10,765,000 | -9,568,000 | 116,482,000 | 35,021,000 | 5,101,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-43,655,000
Investing CF
$-72,695,000
Financing CF
$30,700,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.28
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-390,101,000
Inventory
—
Receivables
—
ST Investments
$125,437,000
EBIT TTM
$-59,863,000
Pretax Income TTM
$-53,320,000
Interest Exp TTM
—
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -56,889,000 | -51,038,000 | 116,482,000 | 5,101,000 | 111,381,000 | -45,650,000 |
| Dec 2024 | 0 | -54,454,000 | -45,567,000 | 160,259,000 | 4,454,000 | 155,805,000 | -42,435,000 |
| Dec 2023 | 2,000,000 | -30,740,000 | -27,876,000 | 96,719,000 | 5,654,000 | 91,065,000 | -23,766,000 |
| Dec 2022 | 0 | -31,055,000 | -30,499,000 | 33,031,000 | 219,981,000 | -186,950,000 | -24,490,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-47,079,000
OpCashFlow TTM
—
Assets (Latest)
$263,430,000
Forward EPS
$-1.35
Max Pain — expiry 2028-12-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $10.11 · call volume: 170 · put volume: 5
Expected Move to 2028-12-15:
±$9.60
(94.96%) —
implied range
$0.51 –
$19.71
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KURA | Kura Oncology, Inc. | $688.17M | $7.49 | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $737.01M | $34.92 | — |
| APMD | Apnimed, Inc. | $741.03M | $17.80 | — |
| OBX | Obsidian Therapeutics, Inc. | $745.61M | $12.07 | — |
| ANNX | Annexon, Inc. | $661.95M | $3.47 | — |
News headlines (Yahoo Finance, 1h cache)
Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
2026-11-12 12:30 · Yahoo
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-10-29 11:00 · Yahoo
Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet
2026-10-23 12:55 · Yahoo
Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
2026-10-23 00:10 · Yahoo
Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
2026-10-22 11:00 · Yahoo
After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
2026-10-15 12:35 · Yahoo
Sagimet Says Denifanstat Shows Continued Improvement in Acne Through 52 Weeks in China Trial
2026-10-09 12:18 · Yahoo
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermat
2026-10-09 11:00 · Yahoo
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
2026-10-04 01:02 · Yahoo
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
2026-10-01 20:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.